Support Care Cancer. 2025 Jul 6;33(7):661. doi: 10.1007/s00520-025-09649-6.
ABSTRACT
PURPOSE: To investigate the clinical characteristics and risk factors associated with medication-related osteonecrosis of the jaw (MRONJ) and to introduce two metrics-equivalent dose (ED) and threshold dose (TD)-as predictive risk assessment tools.
METHODS: In this cross-sectional study, 193 patient records were reviewed from Shahab Dental Clinic and the Oral Medicine Department of Mashhad Dental School (2017-2023). Patients were categorized according to MRONJ stage (0-3) or as “at-risk.” Demographic data, comorbidities, clinical manifestations, and detailed medication profiles were collected. ED for each medication was standardized to the cumulative dose of four years of weekly oral alendronate use (4 × 52 × 70 mg = 14,560 mg). TD was defined as one unit of this ED and served as a cumulative risk cut-off. Statistical analyses included T-tests, ANOVA, and Chi-square tests.
RESULTS: MRONJ was identified in 40.4% of cases, while 59.6% were classified as at-risk. Advanced stages were significantly associated with higher ED, prolonged medication use, and key risk factors, including oncologic diseases, medication type and route of administration, comorbidities, age, and surgical interventions such as extractions and ill-fitting dentures (P < 0.001). The novel metrics demonstrated strong predictive value. ED values were significantly higher in zoledronic acid users compared to denosumab users (2.40 [1.05, 6.00] vs. 1.23 [0.75, 2.37], P < 0.001), and positively correlated with MRONJ severity (R = 0.46, P < 0.001). The odds ratio for MRONJ associated with ED was 1.17 (95% CI: 1.06-1.30).
CONCLUSION: This study offers critical insights into MRONJ risk stratification, highlighting the cumulative impact of medication dose alongside clinical risk factors. The introduction of ED and TD represents a transformative advancement in MRONJ risk prediction, enabling precise prevention strategies and guiding clinical management toward standardized care protocols.
PMID:40619534 | DOI:10.1007/s00520-025-09649-6
